Abstract: A method and apparatus for transporting radiopharmaceuticals. Typically, the apparatus is a two-part assembly, each part having an exterior shell, a radiation shield and a non-porous lining. Additionally, the assembled apparatus has a sealed internal chamber suitable for carrying a syringe or a sharps container containing a syringe. The internal chamber of the radiopharmaceutical pig is lined with a non-porous lining, typically a durable plastic, that prevents contamination of the radiopharmaceutical doses, the radiation shield, or the environment. Additionally, the non-porous lining can be quickly and easily cleaned and sterilized, avoiding the often difficult, to impossible, task of cleaning and sterilizing the radiation shield of the radiopharmaceutical pig. The non-porous lining is surrounded by a radiation shield that is typically comprised of elemental lead. The radiation shield prevents radiation from the radiopharmaceutical from contaminating the user or environment.

Abstract: The invention discloses an interconnection structure and a method for configuring path between the optical networks. The optical network includes a first network and a second network, the first network and the second network each has a number of nodes, a first node of the first network connects with a third node of the second network, a second node of the first network connects with a fourth node of the second network. The method comprises the steps of: setting-up a first path between one of the first node and the second node and another node of the first network; and at least by one link of the link between the first node and the third node and that between the second node and the fourth node, and by the first path, said another node of the first network communicates for path with another node of the second network.

Abstract: The invention described here is the methods of using a hardware-based functional verification system to mimic a design under test (DUT), under intended application environment and software, to record or derive the transition activities of all circuits of the DUT, then calculate the total or partial power consumption during the period of interest. The period of interest is defined by the user in terms of “events” which are the arbitrary states of the DUT. Furthermore, the user can specify the number of sub-divisions required between events thus vary the apparent resolution of the power consumption profile.

Abstract: A method and apparatus for transporting radiopharmaceuticals. Typically, the apparatus is a two-part assembly, each part having an exterior shell, a radiation shield and a non-porous lining. Additionally, the assembled apparatus has a sealed internal chamber suitable for carrying a syringe or a sharps container containing a syringe. The internal chamber of the radiopharmaceutical pig is lined with a non-porous lining, typically a durable plastic, that prevents contamination of the radiopharmaceutical doses, the radiation shield, or the environment. Additionally, the non-porous lining can be quickly and easily cleaned and sterilized, avoiding the often difficult, to impossible, task of cleaning and sterilizing the radiation shield of the radiopharmaceutical pig. The non-porous lining is surrounded by a radiation shield that is typically comprised of elemental lead. The radiation shield prevents radiation from the radiopharmaceutical from contaminating the user or environment.

Abstract: This invention provides pharmaceutical compositions containing compounds for the treatment of neoplasia in mammals. The phosphodiesterase inhibitory activity of a compound is determined along with COX inhibitory activity. Growth inhibitory and apoptosis inducing effects on cultured tumor cells are also determined. Compounds that exhibit phosphodiesterase inhibiton, growth inhibition and apoptosis induction, but prefereably not substantial prostaglandin inhibitory activity, are desirable for the treatment of neoplasia.

Abstract: This invention provides pharmaceutical compositions containing compounds for the treatment of neoplasia in mammals. The phosphodiesterase inhibitory activity of a compound is determined along with COX inhibitory activity. Growth inhibitory and apoptosis inducing effects on cultured tumor cells are also determined. Compounds that exhibit phosphodiesterase inhibiton, growth inhibition and apoptosis induction, but prefereably not substantial prostaglandin inhibitory activity, are desirable for the treatment of neoplasia.

Abstract: A method and apparatus for transporting radiopharmaceuticals. Typically, the apparatus is a two-part assembly, each part having an exterior shell, a radiation shield and a non-porous lining. Additionally, the assembled apparatus has a sealed internal chamber suitable for carrying a syringe or a sharps container containing a syringe. The internal chamber of the radiopharmaceutical pig is lined with a non-porous lining, typically a durable plastic, that prevents contamination of the radiopharmaceutical doses, the radiation shield, or the environment. Additionally, the non-porous lining can be quickly and easily cleaned and sterilized, avoiding the often difficult, to impossible, task of cleaning and sterilizing the radiation shield of the radiopharmaceutical pig. The non-porous lining is surrounded by a radiation shield that is typically comprised of elemental lead. The radiation shield prevents radiation from the radiopharmaceutical from contaminating the user or environment.

Abstract: This invention provides pharmaceutical compositions containing compounds for the treatment of neoplasia in mammals. The phosphodiesterase inhibitory activity of a compound is determined along with COX inhibitory activity. Growth inhibitory and apoptosis inducing effects on cultured tumor cells are also determined. Compounds that exhibit phosphodiesterase inhibiton, growth inhibition and apoptosis induction, but prefereably not substantial prostaglandin inhibitory activity, are desirable for the treatment of neoplasia.

Abstract: An improved method and apparatus for transporting a syringe containing radioactive material that provides many advantages, including the safe enclosure of the syringe both before and after use, which reduces the possibility of contamination of the radiopharmaceutical pig. The present invention also provides a radiopharmaceutical pig that eliminates the need for a protective plastic outer shell and has a convenient grip. Finally, the present invention allows the user to readily determine if a syringe within a closed sharps container is full or spent without handling the container.

Abstract: This invention provides a method for diagnosing a patient with neoplasia.

Abstract: The present invention is directed to a method of modulating inflammation within an immune privileged site in an animal by introducing an effective amount of a Fas ligand fragment comprising the extracellular domain of a full length Fas ligand, a derivative thereof, or a nucleic acid encoding the Fas ligand fragment, behind the blood-tissue barrier of the immune privileged site. In one embodiment the invention pertains to methods of modulating inflammation in the central nervous system generally, at specific lesions in the central nervous system, anterior chamber of the eye, testis, placenta and other immune privileged sites in a mammal. The FasL fragments used in the method of the present invention contain the extracellular domain of FasL and are soluble. The method of the present invention comprises the step of directly administering the FasL fragment, or derivative thereof, or a composition comprising the FasL fragment, or derivative thereof, behind the blood-tissue barrier of the immune privileged site.

Abstract: A method for identifying compounds useful for the treatment of neoplasia involves acertaining whether such compounds exhibit an ability to inhibit a PDE that is characterized by cGMP specificity, cooperative kinetic behavior and insensitivity to phosphorylation.

Abstract: A shielding device and method for injecting a patient with radioactive material from a syringe to reduce exposure of workers to the radioactive material in the syringe. After the injection, the syringe needle falls away from the shield, thereby minimizing the risk of contamination of the shield from the contaminated syringe needle.

Abstract: An improved drawing station system for handling radioactive material for use in syringes in the health care industry. The system includes a drawing station, a syringe shield and two different radiopharmaceutical pigs. The drawing station has a base with a support and two arms mounted thereto to support a first radiopharmaceutical pig enclosing a container of radioactive material. The radiopharmaceutical pig is releasably mounted to the second arm so that the radiopharmaceutical pig is pivotable about two predetermined axes to position the container for penetration by the syringe needle to draw radioactive material from the container into the syringe.

Abstract: An improved radiation dense container for transporting radioactive iodine and the like, including a cup-shaped base having a cavity with an opening that is sized to receive radioactive iodine in the form of either one or more iodine capsules or a vial of iodine solution. The vial has a cap with a septum through which the radioactive iodine solution can be withdrawn from the vial in situ by an oral radioisotope administration set. A lid threadedly engages the base over the cavity opening to substantially seal it when threaded in place and to allow the insertion and removal of the radioactive iodine when removed. The base and the lid are both formed of tungsten. The container includes one or more activated charcoal filters to absorb any gases given off by the radioactive iodine when sealed in the cavity. An inner cup-shaped container and cap, made of plastic and sized and configured for a close fit within the base cavity, may be utilized to conveniently hold the capsules or, optionally, the vial.